Scientists and Religious Leaders Need to Be More Transparent

Scientists and Religious Leaders Need to Be More Transparent

A steeple cross at sunset.

(© Kenneth Keifer/Fotolia)


Keep Reading Keep Reading
Reverend Kevin Fitzgerald
Kevin T. FitzGerald, S.J., Ph.D., Ph.D., is the John A. Creighton University Professor, and an associate professor in the School of Medicine, Department of Medical Education, at Creighton University. He received a Ph.D. in molecular genetics, and a Ph.D. in bioethics, from Georgetown University. His research efforts focus on the utilization of reflection in medical education, the investigation of abnormal gene expression in cancer, and on ethical issues in biomedical research and medical genomics. He has published educational, scientific, and ethical articles in peer-reviewed journals, books, and in the popular press. In addition, Fr. FitzGerald has been a Corresponding Member of the Pontifical Academy for Life since 2005, and a Consultor to the Pontifical Council for Culture since 2014.
A new type of cancer therapy is shrinking deadly brain tumors with just one treatment

MRI scans after a new kind of immunotherapy for brain cancer show remarkable progress in one patient just days after the first treatment.

Mass General Hospital

Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.

But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.

Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

Artificial Intelligence is getting better than humans at detecting breast cancer

A recent study in The Lancet Oncology showed that AI found 20 percent more cancers on mammogram screens than radiologists alone.

The Lancet Oncology

Since the early 2000s, AI systems have eliminated more than 1.7 million jobs, and that number will only increase as AI improves. Some research estimates that by 2025, AI will eliminate more than 85 million jobs.

But for all the talk about job security, AI is also proving to be a powerful tool in healthcare—specifically, cancer detection. One recently published study has shown that, remarkably, artificial intelligence was able to detect 20 percent more cancers in imaging scans than radiologists alone.

Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.